Imaging of the striatal and extrastriatal dopamine transporter with 18F-LBT-999: Quantification, biodistribution, and radiation dosimetry in nonhuman primates (515 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2011 Sep 1; 52(8): 1313-1321.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.381, 5-year impact factor: 6.527
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-80051682570&partnerID=40&md5=b91eaee5d8c61f1431113f1822517248
Keywords: Dopamine Transporter, Radiobiology Dosimetry, Radiotracer Tissue Kinetics, Reference Tissue Method, Methyl 8 (4 Fluoro But 2 En 1 Yl) 3 (4 Tolyl) 8 Azabicyclo[3 2 1]octane 2 Carboxylate F 18, Radiopharmaceutical Agent, Unclassified Drug, Animal Experiment, Article, Caudate Nucleus, Controlled Study, Corpus Striatum, Drug Accumulation, Drug Blood Level, Drug Excretion, Drug Protein Binding, Female, Mesencephalon, Nonhuman, Positron Emission Tomography, Primate, Priority Journal, Putamen, Quantitative Analysis, Radiation Dose Distribution, Radioactivity, Thalamus, Tissue Distribution, Brain, Cocaine, Dopamine Plasma Membrane Transport Proteins, Fluorine Radioisotopes, Macaca Mulatta, Positron-Emission Tomography, Radiometry, Time Factors, X-Ray Computed, Treatment Outcome, Methyl 8 (4 Fluoro But 2 En 1 Yl) 3 (4 Tolyl) 8 Azabicyclo [3 2 1] Octane 2 Carboxylate F 18,
Affiliations:
*** IBB - CNR ***
Department of Clinical Neuroscience, Centre for Psychiatry Research, R5:02, Karolinska Hospital, SE-17176, Stockholm, Sweden
INSERM U930, CHRU Tours, Tours, France
Laboratoires Cyclopharma, Saint Beauzire, France
Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN, United States
Department of Nuclear Medicine, Karolinska Hospital, Stockholm, Sweden
References:
Girault, J.-A., Greengard, P., The Neurobiology of Dopamine Signaling (2004) Archives of Neurology, 61 (5), pp. 641-644. , DOI 10.1001/archneur.61.5.64
Ciliax, B.J., Drash, G.W., Staley, J.K., Haber, S., Mobley, C.J., Miller, G.W., Mufson, E.J., Levey, A.I., Immunocytochemical localization of the dopamine transporter in human brain (1999) Journal of Comparative Neurology, 409 (1), pp. 38-56. , DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4> 3.0.CO
Varrone, A., Halldin, C., Molecular imaging of the dopamine transporter (2010) J Nucl Med, 51, pp. 1331-1334
Jucaite, A., Fernell, E., Halldin, C., Forssberg, H., Farde, L., Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity (2005) Biological Psychiatry, 57 (3), pp. 229-238. , DOI 10.1016/j.biopsych.2004.11.009, PII S0006322304011679
Arakawa, R., Ichimiya, T., Ito, H., Increase in thalamic binding of [11C]PE2I in patients with schizophrenia: A positron emission tomography study of dopamine transporter (2009) J Psychiatr Res, 43, pp. 1219-1223
Chalon, S., Hall, H., Saba, W., Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta- carbomethoxy-3beta-(4′-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter (2006) J Pharmacol Exp Ther, 317, pp. 147-152
Emond, P., Guilloteau, D., Chalon, S., PE2I: A radiopharmaceutical for in vivo exploration of the dopamine transporter (2008) CNS Neurosci Ther, 14, pp. 47-64
Dollé, F., Emond, P., Mavel, S., Synthesis, radiosynthesis and in vivo preliminary evaluation of [ 11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET (2006) Bioorg Med Chem, 14, pp. 1115-1125
Dollé, F., Hinnen, F., Emond, P., Radiosynthesis of [18F]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET (2006) J Labelled Comp Radiopharm, 49, pp. 687-698
Dollé, F., Helfenbein, J., Hinnen, F., One-step radiosynthesis of [18F]LBT-999: A selective radioligand for the visualization of the dopamine transporter with PET (2007) J Labelled Comp Radiopharm, 50, pp. 716-723
Saba, W., Valette, H., Schollhorn-Peyronneau, M.A., [11C]LBT-999: A suitable radioligand for investigation of extra-striatal dopamine transporter with PET (2007) Synapse, 61, pp. 17-23
September 30-October 4, 2006
Athens, , Paper presented at
Clark, J.D., Gebhart, G.F., Gonder, J.C., Keeling, M.E., Kohn, D.F., Special report: The 1996 guide for the care and use of laboratory animals (1997) ILAR J, 38, pp. 41-48
Ryzhikov, N.N., Seneca, N., Krasikova, R.N., Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography (2005) Nucl Med Biol, 32, pp. 109-116
Karlsson, P., Farde, L., Halldin, C., PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor (1993) Psychopharmacology (Berl), 113, pp. 149-156
Varrone, A., Sjoholm, N., Eriksson, L., Gulyas, B., Halldin, C., Farde, L., Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (2009) Eur J Nucl Med Mol Imaging, 36, pp. 1639-1650
Saleem, K.S., Logothesis, N.K., (2007) A Combined MRI and Histology Atlas of the Rhesus Monkey Brain in Stereotaxic Coordinates, , 1st ed. Oxford, U.K.: Academic Press
Melchitzky, D.S., Lewis, D.A., Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum: Evidence for a lobular- and laminar-specific dopamine innervation (2000) Neuropsychopharmacology, 22 (5), pp. 466-472. , DOI 10.1016/S0893-133X(99)00139-6, PII S0893133X99001396
Fujita, M., Seibyl, J.P., Verhoeff, N.P., Kinetic and equilibrium analyses of [123I] epidepride binding to striatal and extrastriatal dopamine D2 receptors (1999) Synapse, 34, pp. 290-304
Carson, R.E., Parameter estimation in PET (1986) Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and the Heart, pp. 287-346. , Phelps M, Schelbert H, eds. New York, NY: Raven Press
Logan, J., Fowler, J.S., Volkow, N.D., Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects (1990) J Cereb Blood Flow Metab, 10, pp. 740-747
Innis, R.B., Cunningham, V.J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R.N., Holden, J., Carson, R.E., Consensus nomenclature for in vivo imaging of reversibly binding radioligands (2007) Journal of Cerebral Blood Flow and Metabolism, 27 (9), pp. 1533-1539. , DOI 10.1038/sj.jcbfm.9600493, PII 9600493
Jucaite, A., Odano, I., Olsson, H., Pauli, S., Halldin, C., Farde, L., Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: A PET study (2006) Eur J Nucl Med Mol Imaging, 33, pp. 657-668
Zoghbi, S.S., Shetty, H.U., Ichise, M., PET imaging of the dopamine transporter with 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements (2006) J Nucl Med, 47, pp. 520-527
Robeson, W., Dhawan, V., Belakhlef, A., Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects (2003) J Nucl Med, 44, pp. 961-966
Sprague, D.R., Chin, F.T., Liow, J.S., Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: Comparison of thin-slice, bisected, and 2-dimensional planar image analysis (2007) J Nucl Med, 48, pp. 100-107
Deloar, H.M., Fujiwara, T., Shidahara, M., Nakamura, T., Watabe, H., Narita, Y., Itoh, M., Watanuki, S., Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging (1998) European Journal of Nuclear Medicine, 25 (6), pp. 565-574. , DOI 10.1007/s002590050257
Verbruggen, A., Coenen, H.H., Deverre, J.R., Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU (2008) Eur J Nucl Med Mol Imaging, 35, pp. 2144-2151
Girault, J. -A., Greengard, P., The Neurobiology of Dopamine Signaling (2004) Archives of Neurology, 61 (5), pp. 641-644. , DOI 10. 1001/archneur. 61. 5. 64
Ciliax, B. J., Drash, G. W., Staley, J. K., Haber, S., Mobley, C. J., Miller, G. W., Mufson, E. J., Levey, A. I., Immunocytochemical localization of the dopamine transporter in human brain (1999) Journal of Comparative Neurology, 409 (1), pp. 38-56. , DOI 10. 1002/ (SICI) 1096-9861 (19990621) 409: 1<38:: AID-CNE4> 3. 0. CO
Doll, F., Emond, P., Mavel, S., Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C] LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET (2006) Bioorg Med Chem, 14, pp. 1115-1125
Doll, F., Hinnen, F., Emond, P., Radiosynthesis of [18F] LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET (2006) J Labelled Comp Radiopharm, 49, pp. 687-698
Doll, F., Helfenbein, J., Hinnen, F., One-step radiosynthesis of [18F] LBT-999: A selective radioligand for the visualization of the dopamine transporter with PET (2007) J Labelled Comp Radiopharm, 50, pp. 716-723
Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., Kohn, D. F., Special report: The 1996 guide for the care and use of laboratory animals (1997) ILAR J, 38, pp. 41-48
Ryzhikov, N. N., Seneca, N., Krasikova, R. N., Preparation of highly specific radioactivity [18F] flumazenil and its evaluation in cynomolgus monkey by positron emission tomography (2005) Nucl Med Biol, 32, pp. 109-116
Saleem, K. S., Logothesis, N. K., (2007) A Combined MRI and Histology Atlas of the Rhesus Monkey Brain in Stereotaxic Coordinates, , 1st ed. Oxford, U. K.: Academic Press
Melchitzky, D. S., Lewis, D. A., Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum: Evidence for a lobular- and laminar-specific dopamine innervation (2000) Neuropsychopharmacology, 22 (5), pp. 466-472. , DOI 10. 1016/S0893-133X (99) 00139-6, PII S0893133X99001396
Carson, R. E., Parameter estimation in PET (1986) Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and the Heart, pp. 287-346. , Phelps M, Schelbert H, eds. New York, NY: Raven Press
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Carson, R. E., Consensus nomenclature for in vivo imaging of reversibly binding radioligands (2007) Journal of Cerebral Blood Flow and Metabolism, 27 (9), pp. 1533-1539. , DOI 10. 1038/sj. jcbfm. 9600493, PII 9600493
Zoghbi, S. S., Shetty, H. U., Ichise, M., PET imaging of the dopamine transporter with 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements (2006) J Nucl Med, 47, pp. 520-527
Sprague, D. R., Chin, F. T., Liow, J. S., Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F] SPA-RQ: Comparison of thin-slice, bisected, and 2-dimensional planar image analysis (2007) J Nucl Med, 48, pp. 100-107
Deloar, H. M., Fujiwara, T., Shidahara, M., Nakamura, T., Watabe, H., Narita, Y., Itoh, M., Watanuki, S., Estimation of absorbed dose for 2- [F-18] fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging (1998) European Journal of Nuclear Medicine, 25 (6), pp. 565-574. , DOI 10. 1007/s002590050257
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2011 Sep 1; 52(8): 1313-1321.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.381, 5-year impact factor: 6.527
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-80051682570&partnerID=40&md5=b91eaee5d8c61f1431113f1822517248
Keywords: Dopamine Transporter, Radiobiology Dosimetry, Radiotracer Tissue Kinetics, Reference Tissue Method, Methyl 8 (4 Fluoro But 2 En 1 Yl) 3 (4 Tolyl) 8 Azabicyclo[3 2 1]octane 2 Carboxylate F 18, Radiopharmaceutical Agent, Unclassified Drug, Animal Experiment, Article, Caudate Nucleus, Controlled Study, Corpus Striatum, Drug Accumulation, Drug Blood Level, Drug Excretion, Drug Protein Binding, Female, Mesencephalon, Nonhuman, Positron Emission Tomography, Primate, Priority Journal, Putamen, Quantitative Analysis, Radiation Dose Distribution, Radioactivity, Thalamus, Tissue Distribution, Brain, Cocaine, Dopamine Plasma Membrane Transport Proteins, Fluorine Radioisotopes, Macaca Mulatta, Positron-Emission Tomography, Radiometry, Time Factors, X-Ray Computed, Treatment Outcome, Methyl 8 (4 Fluoro But 2 En 1 Yl) 3 (4 Tolyl) 8 Azabicyclo [3 2 1] Octane 2 Carboxylate F 18,
Affiliations:
*** IBB - CNR ***
Department of Clinical Neuroscience, Centre for Psychiatry Research, R5:02, Karolinska Hospital, SE-17176, Stockholm, Sweden
INSERM U930, CHRU Tours, Tours, France
Laboratoires Cyclopharma, Saint Beauzire, France
Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN, United States
Department of Nuclear Medicine, Karolinska Hospital, Stockholm, Sweden
References:
Girault, J.-A., Greengard, P., The Neurobiology of Dopamine Signaling (2004) Archives of Neurology, 61 (5), pp. 641-644. , DOI 10.1001/archneur.61.5.64
Ciliax, B.J., Drash, G.W., Staley, J.K., Haber, S., Mobley, C.J., Miller, G.W., Mufson, E.J., Levey, A.I., Immunocytochemical localization of the dopamine transporter in human brain (1999) Journal of Comparative Neurology, 409 (1), pp. 38-56. , DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4> 3.0.CO
Varrone, A., Halldin, C., Molecular imaging of the dopamine transporter (2010) J Nucl Med, 51, pp. 1331-1334
Jucaite, A., Fernell, E., Halldin, C., Forssberg, H., Farde, L., Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity (2005) Biological Psychiatry, 57 (3), pp. 229-238. , DOI 10.1016/j.biopsych.2004.11.009, PII S0006322304011679
Arakawa, R., Ichimiya, T., Ito, H., Increase in thalamic binding of [11C]PE2I in patients with schizophrenia: A positron emission tomography study of dopamine transporter (2009) J Psychiatr Res, 43, pp. 1219-1223
Chalon, S., Hall, H., Saba, W., Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta- carbomethoxy-3beta-(4′-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter (2006) J Pharmacol Exp Ther, 317, pp. 147-152
Emond, P., Guilloteau, D., Chalon, S., PE2I: A radiopharmaceutical for in vivo exploration of the dopamine transporter (2008) CNS Neurosci Ther, 14, pp. 47-64
Dollé, F., Emond, P., Mavel, S., Synthesis, radiosynthesis and in vivo preliminary evaluation of [ 11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET (2006) Bioorg Med Chem, 14, pp. 1115-1125
Dollé, F., Hinnen, F., Emond, P., Radiosynthesis of [18F]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET (2006) J Labelled Comp Radiopharm, 49, pp. 687-698
Dollé, F., Helfenbein, J., Hinnen, F., One-step radiosynthesis of [18F]LBT-999: A selective radioligand for the visualization of the dopamine transporter with PET (2007) J Labelled Comp Radiopharm, 50, pp. 716-723
Saba, W., Valette, H., Schollhorn-Peyronneau, M.A., [11C]LBT-999: A suitable radioligand for investigation of extra-striatal dopamine transporter with PET (2007) Synapse, 61, pp. 17-23
September 30-October 4, 2006
Athens, , Paper presented at
Clark, J.D., Gebhart, G.F., Gonder, J.C., Keeling, M.E., Kohn, D.F., Special report: The 1996 guide for the care and use of laboratory animals (1997) ILAR J, 38, pp. 41-48
Ryzhikov, N.N., Seneca, N., Krasikova, R.N., Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography (2005) Nucl Med Biol, 32, pp. 109-116
Karlsson, P., Farde, L., Halldin, C., PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor (1993) Psychopharmacology (Berl), 113, pp. 149-156
Varrone, A., Sjoholm, N., Eriksson, L., Gulyas, B., Halldin, C., Farde, L., Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (2009) Eur J Nucl Med Mol Imaging, 36, pp. 1639-1650
Saleem, K.S., Logothesis, N.K., (2007) A Combined MRI and Histology Atlas of the Rhesus Monkey Brain in Stereotaxic Coordinates, , 1st ed. Oxford, U.K.: Academic Press
Melchitzky, D.S., Lewis, D.A., Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum: Evidence for a lobular- and laminar-specific dopamine innervation (2000) Neuropsychopharmacology, 22 (5), pp. 466-472. , DOI 10.1016/S0893-133X(99)00139-6, PII S0893133X99001396
Fujita, M., Seibyl, J.P., Verhoeff, N.P., Kinetic and equilibrium analyses of [123I] epidepride binding to striatal and extrastriatal dopamine D2 receptors (1999) Synapse, 34, pp. 290-304
Carson, R.E., Parameter estimation in PET (1986) Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and the Heart, pp. 287-346. , Phelps M, Schelbert H, eds. New York, NY: Raven Press
Logan, J., Fowler, J.S., Volkow, N.D., Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects (1990) J Cereb Blood Flow Metab, 10, pp. 740-747
Innis, R.B., Cunningham, V.J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R.N., Holden, J., Carson, R.E., Consensus nomenclature for in vivo imaging of reversibly binding radioligands (2007) Journal of Cerebral Blood Flow and Metabolism, 27 (9), pp. 1533-1539. , DOI 10.1038/sj.jcbfm.9600493, PII 9600493
Jucaite, A., Odano, I., Olsson, H., Pauli, S., Halldin, C., Farde, L., Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: A PET study (2006) Eur J Nucl Med Mol Imaging, 33, pp. 657-668
Zoghbi, S.S., Shetty, H.U., Ichise, M., PET imaging of the dopamine transporter with 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements (2006) J Nucl Med, 47, pp. 520-527
Robeson, W., Dhawan, V., Belakhlef, A., Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects (2003) J Nucl Med, 44, pp. 961-966
Sprague, D.R., Chin, F.T., Liow, J.S., Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: Comparison of thin-slice, bisected, and 2-dimensional planar image analysis (2007) J Nucl Med, 48, pp. 100-107
Deloar, H.M., Fujiwara, T., Shidahara, M., Nakamura, T., Watabe, H., Narita, Y., Itoh, M., Watanuki, S., Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging (1998) European Journal of Nuclear Medicine, 25 (6), pp. 565-574. , DOI 10.1007/s002590050257
Verbruggen, A., Coenen, H.H., Deverre, J.R., Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU (2008) Eur J Nucl Med Mol Imaging, 35, pp. 2144-2151
Girault, J. -A., Greengard, P., The Neurobiology of Dopamine Signaling (2004) Archives of Neurology, 61 (5), pp. 641-644. , DOI 10. 1001/archneur. 61. 5. 64
Ciliax, B. J., Drash, G. W., Staley, J. K., Haber, S., Mobley, C. J., Miller, G. W., Mufson, E. J., Levey, A. I., Immunocytochemical localization of the dopamine transporter in human brain (1999) Journal of Comparative Neurology, 409 (1), pp. 38-56. , DOI 10. 1002/ (SICI) 1096-9861 (19990621) 409: 1<38:: AID-CNE4> 3. 0. CO
Doll, F., Emond, P., Mavel, S., Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C] LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET (2006) Bioorg Med Chem, 14, pp. 1115-1125
Doll, F., Hinnen, F., Emond, P., Radiosynthesis of [18F] LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET (2006) J Labelled Comp Radiopharm, 49, pp. 687-698
Doll, F., Helfenbein, J., Hinnen, F., One-step radiosynthesis of [18F] LBT-999: A selective radioligand for the visualization of the dopamine transporter with PET (2007) J Labelled Comp Radiopharm, 50, pp. 716-723
Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., Kohn, D. F., Special report: The 1996 guide for the care and use of laboratory animals (1997) ILAR J, 38, pp. 41-48
Ryzhikov, N. N., Seneca, N., Krasikova, R. N., Preparation of highly specific radioactivity [18F] flumazenil and its evaluation in cynomolgus monkey by positron emission tomography (2005) Nucl Med Biol, 32, pp. 109-116
Saleem, K. S., Logothesis, N. K., (2007) A Combined MRI and Histology Atlas of the Rhesus Monkey Brain in Stereotaxic Coordinates, , 1st ed. Oxford, U. K.: Academic Press
Melchitzky, D. S., Lewis, D. A., Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum: Evidence for a lobular- and laminar-specific dopamine innervation (2000) Neuropsychopharmacology, 22 (5), pp. 466-472. , DOI 10. 1016/S0893-133X (99) 00139-6, PII S0893133X99001396
Carson, R. E., Parameter estimation in PET (1986) Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and the Heart, pp. 287-346. , Phelps M, Schelbert H, eds. New York, NY: Raven Press
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Carson, R. E., Consensus nomenclature for in vivo imaging of reversibly binding radioligands (2007) Journal of Cerebral Blood Flow and Metabolism, 27 (9), pp. 1533-1539. , DOI 10. 1038/sj. jcbfm. 9600493, PII 9600493
Zoghbi, S. S., Shetty, H. U., Ichise, M., PET imaging of the dopamine transporter with 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements (2006) J Nucl Med, 47, pp. 520-527
Sprague, D. R., Chin, F. T., Liow, J. S., Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F] SPA-RQ: Comparison of thin-slice, bisected, and 2-dimensional planar image analysis (2007) J Nucl Med, 48, pp. 100-107
Deloar, H. M., Fujiwara, T., Shidahara, M., Nakamura, T., Watabe, H., Narita, Y., Itoh, M., Watanuki, S., Estimation of absorbed dose for 2- [F-18] fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging (1998) European Journal of Nuclear Medicine, 25 (6), pp. 565-574. , DOI 10. 1007/s002590050257
Imaging of the striatal and extrastriatal dopamine transporter with 18F-LBT-999: Quantification, biodistribution, and radiation dosimetry in nonhuman primates
The aim of this study was to evaluate the quantification, biodistribution, and radiation dosimetry of the novel dopamine transporter (DAT) radioligand 18F-(2S,3S)-methyl 8-((E)-4-fluorobut-2-en-1-yl)-3-(p-tolyl)-8- azabicyclo[3.2.1]octane-2-carboxylate (18F-LBT-999) in nonhuman primates. Methods: The brain study was conducted in 4 female rhesus monkeys. PET measurements were conducted for 243 min using the high-resolution research tomograph (HRRT) with the measurement of the metabolite-corrected arterial input function and protein binding. Quantification was performed with kinetic analysis using 2-tissue- and 1-tissue-compartment models, with Logan graphical analysis and with different reference tissue models. The outcome measures were total distribution volume (VT), nondisplaceable distribution volume (VND), binding potential relative to the free concentration of radioligand in plasma (BPF), and binding potential relative to the concentration of nondisplaceable radioligand in tissue (BPND) = VT - VND/VND using the cerebellum as a reference region. For the biodistribution and radiation dosimetry, 2 female cynomolgus monkeys were studied.Whole-body PET scans were obtained using a PET/CT system for approximately 250 min. Estimates of the absorbed radiation dose in humans were calculated using OLINDA/EXM software. Results: 18F-LBT-999 showed good brain uptake (300% standardized uptake value) and regional distribution according to known DAT density. The 2-tissuecompartment model was the preferred model for the quantification. Late peak equilibrium (120-140 min) and slow washout were observed in the striatum, with high variability of VT, BPF, and BPND. When the different models were compared with the 2-tissuecompartment model, the underestimation of VT or BPND was larger in the caudate and putamen than in the midbrain and thalamus. The reference tissue models were suitable for the quantification. The whole-body distribution study showed that the main routes of excretion of 18F-LBT-999 were the urinary and gastrointestinal systems, with the bladder being the critical organ. Accumulation of 18F-LBT-999 was found in the bone and skull, with a relatively high dose estimated for the osteogenic cells. The range of calculated effective dose was 0.021-0.022 mSv/MBq. Conclusion: 18F-LBT-999 seemed to be a suitable PET radioligand for the DAT quantification, particularly for extrastriatal regions. The skull uptake did not seem to be a limitation for brain imaging. The calculated dosimetry estimates based on data in nonhuman primates seemed comparable with those of other clinically used 18F-labeled radioligands, for example, 18F-FDG (0.024-0.027 mSv/MBq). Copyright © 2011 by the Society of Nuclear Medicine, Inc.
The aim of this study was to evaluate the quantification, biodistribution, and radiation dosimetry of the novel dopamine transporter (DAT) radioligand 18F-(2S,3S)-methyl 8-((E)-4-fluorobut-2-en-1-yl)-3-(p-tolyl)-8- azabicyclo[3.2.1]octane-2-carboxylate (18F-LBT-999) in nonhuman primates. Methods: The brain study was conducted in 4 female rhesus monkeys. PET measurements were conducted for 243 min using the high-resolution research tomograph (HRRT) with the measurement of the metabolite-corrected arterial input function and protein binding. Quantification was performed with kinetic analysis using 2-tissue- and 1-tissue-compartment models, with Logan graphical analysis and with different reference tissue models. The outcome measures were total distribution volume (VT), nondisplaceable distribution volume (VND), binding potential relative to the free concentration of radioligand in plasma (BPF), and binding potential relative to the concentration of nondisplaceable radioligand in tissue (BPND) = VT - VND/VND using the cerebellum as a reference region. For the biodistribution and radiation dosimetry, 2 female cynomolgus monkeys were studied.Whole-body PET scans were obtained using a PET/CT system for approximately 250 min. Estimates of the absorbed radiation dose in humans were calculated using OLINDA/EXM software. Results: 18F-LBT-999 showed good brain uptake (300% standardized uptake value) and regional distribution according to known DAT density. The 2-tissuecompartment model was the preferred model for the quantification. Late peak equilibrium (120-140 min) and slow washout were observed in the striatum, with high variability of VT, BPF, and BPND. When the different models were compared with the 2-tissuecompartment model, the underestimation of VT or BPND was larger in the caudate and putamen than in the midbrain and thalamus. The reference tissue models were suitable for the quantification. The whole-body distribution study showed that the main routes of excretion of 18F-LBT-999 were the urinary and gastrointestinal systems, with the bladder being the critical organ. Accumulation of 18F-LBT-999 was found in the bone and skull, with a relatively high dose estimated for the osteogenic cells. The range of calculated effective dose was 0.021-0.022 mSv/MBq. Conclusion: 18F-LBT-999 seemed to be a suitable PET radioligand for the DAT quantification, particularly for extrastriatal regions. The skull uptake did not seem to be a limitation for brain imaging. The calculated dosimetry estimates based on data in nonhuman primates seemed comparable with those of other clinically used 18F-labeled radioligands, for example, 18F-FDG (0.024-0.027 mSv/MBq). Copyright © 2011 by the Society of Nuclear Medicine, Inc.
Imaging of the striatal and extrastriatal dopamine transporter with 18F-LBT-999: Quantification, biodistribution, and radiation dosimetry in nonhuman primates
No results. |
Imaging of the striatal and extrastriatal dopamine transporter with 18F-LBT-999: Quantification, biodistribution, and radiation dosimetry in nonhuman primates
Other filter: ([btitle,keywords] "Dopamine Transporter ...
Russo C, Pontillo G, Saccà F, Riccio E, Cocozza S, Pane C, Tedeschi E, Pisani A, Pappata S
* Nonvascular Parkinsonism in Fabry Disease: Results From Magnetic Resonance and Dopamine Transporter Imaging (19 views)
J Neuropathol Exp Neurol (ISSN: 0022-3069linking), 2021 Apr 16; 80(5): 476-479.
Impact Factor: 2.923
View Export to BibTeX Export to EndNote
Erro R, Landolfi A, D , #xagostino G, Pace L, Picillo M, Scarano M, Cuocolo A, Pappata S, Vitale C, Pellecchia MT, Monteleone P, Barone P
* Bipolar Disorder and Parkinson's Disease: A (123)I-Ioflupane Dopamine Transporter SPECT Study (6 views)
Front Neurol (ISSN: 1664-2295linking), 2021 Apr 13; 12: 652375-652375.
Impact Factor: 3.77
View Export to BibTeX Export to EndNote
Greco A, Zannetti A, Pappata S, Albanese S, Coda AR, Ragucci M, Nardelli A, Brunetti A, Cuocolo A, Salvatore M
* Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation (465 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785linking, 1824-4785print, 1827-1936electronic), 2018 Mar; 62(1): 112-117.
Impact Factor: 2.413
View Export to BibTeX Export to EndNote
Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, Erro R, Longo K, Vicidomini C, Pellecchia MT, Amboni M, Brunetti A, Salvatore M, Barone P, Pappata S
* Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients (347 views)
Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1353-8020print), 2015 May; 21(5): 489-493.
Impact Factor: 3.794
View Export to BibTeX Export to EndNote
Pellecchia MT, Picillo M, Santangelo G, Longo K, Moccia M, Erro R, Amboni M, Vitale C, Vicidomini C, Salvatore M, Barone P, Pappata S
* Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study (481 views)
Acta Neurol Scand (ISSN: 0001-6314, 1600-0404), 2015 Feb 3; 131(5): 275-281.
Impact Factor: 2.559
View Export to BibTeX Export to EndNote
Moccia M, Pappata S, Erro R, Picillo M, Vitale C, Amboni M, Longo K, Palladino R, Barone P, Pellecchia MT
* Uric Acid Relates To Dopamine Transporter Availability In Parkinson'S Disease (418 views)
Acta Neurol Scand (ISSN: 0001-6314, 1600-0404), 2015; 131(2): 127-131.
Impact Factor: 2.559
View Export to BibTeX Export to EndNote
Moccia M, Pappata S, Picillo M, Erro R, Coda ARD, Longo K, Vitale C, Amboni M, Brunetti A, Capo G, Salvatore M, Barone P, Pellecchia MT
* Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease (638 views)
J Neurol (ISSN: 0340-5354, 1432-1459, 0340-5354print), 2014 Nov; 261(11): 2112-2118.
Impact Factor: 3.377
View Export to BibTeX Export to EndNote
Olgiati S, De Rosa A, Quadri M, Criscuolo C, Breedveld GJ, Picillo M, Pappata S, Quarantelli M, Barone P, De Michele G, Bonifati V
* Park20 Caused By Synj1 Homozygous Arg258gln Mutation In A New Italian Family (476 views)
Neurogenetics (ISSN: 1364-6745, 1364-6753), 2014 Aug; 15(3): 183-188.
Impact Factor: 2.884
View Export to BibTeX Export to EndNote
Greco A, Zannetti A, Coda ARD, Albanese S, Nardelli A, Roca A, Pappata S, Brunetti A, Cuocolo A
* Effects of Thyroid Blockade on Brain Imaging of Dopamine Transporter in Normal Mice (347 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Erro R, Pappata S, Amboni M, Vicidomini C, Longo K, Santangelo G, Picillo M, Vitale C, Moccia M, Giordano F, Brunetti A, Pellecchia MT, Salvatore M, Barone P
* Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients (493 views)
Parkinsonism Relat D (ISSN: 1873-5126, 1353-8020, 1873-5126electronic), 2012 Nov; 18(9): 1034-1038.
Impact Factor: 3.274
View Export to BibTeX Export to EndNote
Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T
* Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I (492 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Jul; 53(7): 1065-1073.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G
* The relationship between cerebral vascular disease and parkinsonism: The VADO study (496 views)
Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780.
Impact Factor: 3.274
View Export to BibTeX Export to EndNote
Varrone A, Halldin C
Molecular imaging of the dopamine transporter (542 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2010 Sep 1; 51(9): 1331-1334.
Impact Factor: 7.022
View Export to BibTeX Export to EndNote
Darcourt J, Booij J, Tatsch K, Varrone A, Borght TV, Kapucu OL, Nagren K, Nobili F, Walker Z, Van Laere K
* EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version (723 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Feb; 37(2): 443-450.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L
* Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (604 views) (PDF 259 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Oct; 36(10): 1639-1650.
Impact Factor: 4.531
View Export to BibTeX Export to EndNote
Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, Gulyas B, Halldin C
* In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand (534 views)
Synapse (ISSN: 0887-4476), 2009 Oct; 63(10): 871-880.
Impact Factor: 2.557
View Export to BibTeX Export to EndNote
Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, Filla A, Barone P, Pappata S, Salvatore M
* Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT (341 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Jul; 35(7): 1343-1349.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Pellecchia MT, Varrone A, Annesi G, Amboni M, Cicarelli G, Sansone V, Annesi F, Rocca FE, Vitale C, Pappata S, Quattrone A, Barone P
* Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: An FP-CIT SPECT study (318 views)
Mov Disord (ISSN: 0885-3185, 1531-8257, 0885-3185linking), 2007 Mar 15; 22(4): 559-563.
Impact Factor: 3.207
View Export to BibTeX Export to EndNote
Varrone A, Sansone V, Pellecchia MT, Amboni M, Vitale C, Salvatore E, De Michele G, Garavaglia B, Annesi G, Brice A, Pappata S, Barone P, Salvatore M
* Longitudinal changes of dopamine transporter density in early-onset parkin disease measured with [I-123]FP-CIT SPECT (221 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Sep; 33: N/D-N/D.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Salvatore E, Varrone A, Sansone V, Nolano M, Bruni AC, De Rosa A, Santoro L, Pappata S, Filla A, De Michele G
* Characterization of nigrostriatal dysfunction in spinocerebellar ataxia 17 (297 views)
Mov Disord (ISSN: 0885-3185, 1531-8257, 0885-3185linking), 2006 Jun; 21(6): 872-875.
Impact Factor: 3.323
View Export to BibTeX Export to EndNote
Sansone V, Varrone A, Pellecchia MT, Amboni M, Salvatore E, De Michele G, Filla A, Barone P, Pappata S, Salvatore M
* Comparison Of A Dual-Headed And A Brain-Dedicated SPECT Camera In The Ability To Measure The Loss Of Dopamine Transporters With [123I]FP-CIT (308 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Varrone A, Salvatore E, Sansone V, De Michele G, Filla A, Pappata S, Salvatore M
* [123I]FP-CIT SPECT Study Of The Striatal Dopamine Transporter Density In Patients With Idiopathic Late Onset Cerebellar Ataxia And MSA-C (237 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, Garavaglia B, Brice A, Brunetti A, Bonavita V, De Michele G, Salvatore M, Pappata S, Barone P
* Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease (4017 views)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2004 Dec 14; 63(11): 2097-2103.
Impact Factor: 5.973
View Export to BibTeX Export to EndNote
Varrone A, Salvatore E, De Michele G, Barone P, Sansone V, Pellecchia MT, Castaldo I, Coppola G, Brunetti A, Salvatore M, Pappata S, Filla A
* Reduced Striatal [123I]FP-CIT Binding in SCA2 Patients without Parkinsonism (425 views)
Annals Of Neurology, 2004 Mar; 55(3): 426-430.
Impact Factor: 11.91
View Export to BibTeX Export to EndNote
* Nonvascular Parkinsonism in Fabry Disease: Results From Magnetic Resonance and Dopamine Transporter Imaging (19 views)
J Neuropathol Exp Neurol (ISSN: 0022-3069linking), 2021 Apr 16; 80(5): 476-479.
Impact Factor: 2.923
View Export to BibTeX Export to EndNote
Erro R, Landolfi A, D , #xagostino G, Pace L, Picillo M, Scarano M, Cuocolo A, Pappata S, Vitale C, Pellecchia MT, Monteleone P, Barone P
* Bipolar Disorder and Parkinson's Disease: A (123)I-Ioflupane Dopamine Transporter SPECT Study (6 views)
Front Neurol (ISSN: 1664-2295linking), 2021 Apr 13; 12: 652375-652375.
Impact Factor: 3.77
View Export to BibTeX Export to EndNote
Greco A, Zannetti A, Pappata S, Albanese S, Coda AR, Ragucci M, Nardelli A, Brunetti A, Cuocolo A, Salvatore M
* Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation (465 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785linking, 1824-4785print, 1827-1936electronic), 2018 Mar; 62(1): 112-117.
Impact Factor: 2.413
View Export to BibTeX Export to EndNote
Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, Erro R, Longo K, Vicidomini C, Pellecchia MT, Amboni M, Brunetti A, Salvatore M, Barone P, Pappata S
* Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients (347 views)
Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1353-8020print), 2015 May; 21(5): 489-493.
Impact Factor: 3.794
View Export to BibTeX Export to EndNote
Pellecchia MT, Picillo M, Santangelo G, Longo K, Moccia M, Erro R, Amboni M, Vitale C, Vicidomini C, Salvatore M, Barone P, Pappata S
* Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study (481 views)
Acta Neurol Scand (ISSN: 0001-6314, 1600-0404), 2015 Feb 3; 131(5): 275-281.
Impact Factor: 2.559
View Export to BibTeX Export to EndNote
Moccia M, Pappata S, Erro R, Picillo M, Vitale C, Amboni M, Longo K, Palladino R, Barone P, Pellecchia MT
* Uric Acid Relates To Dopamine Transporter Availability In Parkinson'S Disease (418 views)
Acta Neurol Scand (ISSN: 0001-6314, 1600-0404), 2015; 131(2): 127-131.
Impact Factor: 2.559
View Export to BibTeX Export to EndNote
Moccia M, Pappata S, Picillo M, Erro R, Coda ARD, Longo K, Vitale C, Amboni M, Brunetti A, Capo G, Salvatore M, Barone P, Pellecchia MT
* Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease (638 views)
J Neurol (ISSN: 0340-5354, 1432-1459, 0340-5354print), 2014 Nov; 261(11): 2112-2118.
Impact Factor: 3.377
View Export to BibTeX Export to EndNote
Olgiati S, De Rosa A, Quadri M, Criscuolo C, Breedveld GJ, Picillo M, Pappata S, Quarantelli M, Barone P, De Michele G, Bonifati V
* Park20 Caused By Synj1 Homozygous Arg258gln Mutation In A New Italian Family (476 views)
Neurogenetics (ISSN: 1364-6745, 1364-6753), 2014 Aug; 15(3): 183-188.
Impact Factor: 2.884
View Export to BibTeX Export to EndNote
Greco A, Zannetti A, Coda ARD, Albanese S, Nardelli A, Roca A, Pappata S, Brunetti A, Cuocolo A
* Effects of Thyroid Blockade on Brain Imaging of Dopamine Transporter in Normal Mice (347 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Erro R, Pappata S, Amboni M, Vicidomini C, Longo K, Santangelo G, Picillo M, Vitale C, Moccia M, Giordano F, Brunetti A, Pellecchia MT, Salvatore M, Barone P
* Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients (493 views)
Parkinsonism Relat D (ISSN: 1873-5126, 1353-8020, 1873-5126electronic), 2012 Nov; 18(9): 1034-1038.
Impact Factor: 3.274
View Export to BibTeX Export to EndNote
Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T
* Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I (492 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Jul; 53(7): 1065-1073.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G
* The relationship between cerebral vascular disease and parkinsonism: The VADO study (496 views)
Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780.
Impact Factor: 3.274
View Export to BibTeX Export to EndNote
Varrone A, Halldin C
Molecular imaging of the dopamine transporter (542 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2010 Sep 1; 51(9): 1331-1334.
Impact Factor: 7.022
View Export to BibTeX Export to EndNote
Darcourt J, Booij J, Tatsch K, Varrone A, Borght TV, Kapucu OL, Nagren K, Nobili F, Walker Z, Van Laere K
* EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version (723 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Feb; 37(2): 443-450.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L
* Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (604 views) (PDF 259 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Oct; 36(10): 1639-1650.
Impact Factor: 4.531
View Export to BibTeX Export to EndNote
Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, Gulyas B, Halldin C
* In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand (534 views)
Synapse (ISSN: 0887-4476), 2009 Oct; 63(10): 871-880.
Impact Factor: 2.557
View Export to BibTeX Export to EndNote
Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, Filla A, Barone P, Pappata S, Salvatore M
* Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT (341 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Jul; 35(7): 1343-1349.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Pellecchia MT, Varrone A, Annesi G, Amboni M, Cicarelli G, Sansone V, Annesi F, Rocca FE, Vitale C, Pappata S, Quattrone A, Barone P
* Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: An FP-CIT SPECT study (318 views)
Mov Disord (ISSN: 0885-3185, 1531-8257, 0885-3185linking), 2007 Mar 15; 22(4): 559-563.
Impact Factor: 3.207
View Export to BibTeX Export to EndNote
Varrone A, Sansone V, Pellecchia MT, Amboni M, Vitale C, Salvatore E, De Michele G, Garavaglia B, Annesi G, Brice A, Pappata S, Barone P, Salvatore M
* Longitudinal changes of dopamine transporter density in early-onset parkin disease measured with [I-123]FP-CIT SPECT (221 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Sep; 33: N/D-N/D.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Salvatore E, Varrone A, Sansone V, Nolano M, Bruni AC, De Rosa A, Santoro L, Pappata S, Filla A, De Michele G
* Characterization of nigrostriatal dysfunction in spinocerebellar ataxia 17 (297 views)
Mov Disord (ISSN: 0885-3185, 1531-8257, 0885-3185linking), 2006 Jun; 21(6): 872-875.
Impact Factor: 3.323
View Export to BibTeX Export to EndNote
Sansone V, Varrone A, Pellecchia MT, Amboni M, Salvatore E, De Michele G, Filla A, Barone P, Pappata S, Salvatore M
* Comparison Of A Dual-Headed And A Brain-Dedicated SPECT Camera In The Ability To Measure The Loss Of Dopamine Transporters With [123I]FP-CIT (308 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Varrone A, Salvatore E, Sansone V, De Michele G, Filla A, Pappata S, Salvatore M
* [123I]FP-CIT SPECT Study Of The Striatal Dopamine Transporter Density In Patients With Idiopathic Late Onset Cerebellar Ataxia And MSA-C (237 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, Garavaglia B, Brice A, Brunetti A, Bonavita V, De Michele G, Salvatore M, Pappata S, Barone P
* Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease (4017 views)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2004 Dec 14; 63(11): 2097-2103.
Impact Factor: 5.973
View Export to BibTeX Export to EndNote
Varrone A, Salvatore E, De Michele G, Barone P, Sansone V, Pellecchia MT, Castaldo I, Coppola G, Brunetti A, Salvatore M, Pappata S, Filla A
* Reduced Striatal [123I]FP-CIT Binding in SCA2 Patients without Parkinsonism (425 views)
Annals Of Neurology, 2004 Mar; 55(3): 426-430.
Impact Factor: 11.91
View Export to BibTeX Export to EndNote
24 Records (19 excluding Abstracts).
Total impact factor: 101.716 (82.133 excluding Abstracts).
Total 5 year impact factor: 104.062 (82.785 excluding Abstracts).
Total impact factor: 101.716 (82.133 excluding Abstracts).
Total 5 year impact factor: 104.062 (82.785 excluding Abstracts).
515 views. Last view on Friday 24 March 2023, 7:15:07
ibb.cnr.it
